InnovaRx Innova Health Strategies

F98.0

Enuresis not due to a substance or known physiological condition

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 7 never code together
F98code
Excludes2
  • breath-holding spells (R06.89)R06.89
  • gender identity disorder of childhood (F64.2)F64.2
  • Kleine-Levin syndrome (G47.13)G47.13
  • obsessive-compulsive disorder (F42.-)F42.-
  • sleep disorders not due to a substance or known physiological condition (F51.-)F51.-
F98.0code
Excludes1
F01-F99chapter
Excludes2
  • symptoms, signs and abnormal clinical laboratory findings, not elsewhere classified (R00-R99)R00-R99

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Excludes2 — not included here, but the patient may have both. Code both when documented.

Instructional notes 6
F98.0code
Inclusion terms
  • Enuresis (primary) (secondary) of nonorganic origin
  • Functional enuresis
  • Psychogenic enuresis
  • Urinary incontinence of nonorganic origin
F90-F98block
Notes
  • Codes within categories F90-F98 may be used regardless of the age of a patient. These disorders generally have onset within the childhood or adolescent years, but may continue throughout life or not be diagnosed until adulthoodF90-F98
F01-F99chapter
Includes
  • disorders of psychological development
Index entries leading here 4
  • Enuresis R32
  • Problem (with) (related to)
  • Urine
    • enuresis, nonorganic origin F98.0
    • incontinence R32
      • nonorganic origin F98.0
  • Incontinence R32
    • urine (urinary) R32
      • nonorganic origin F98.0
Alongside this code 7 same parent — F98
Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

Maps to no condition category in any loaded model.

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
F98
Block
F90-F98
Siblings
7

Present FY2024–FY2027.